Sakiko Chikazawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sakiko Chikazawa has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Kazumoto Katagiri
Department of Dermatology Dokkyo Medical University Saitama Medical Center Saitama Japan
2 shared publications - Keisuke Kobayashi
Department of Dermatology Dokkyo Medical University Saitama Medical Centre Koshigaya Japan
2 shared publications - Nao Ichimasu
Department of Dermatology Dokkyo Medical University Saitama Medical Center Saitama Japan
2 shared publications - So Suzuki
Department of Dermatology Dokkyo Medical University Saitama Medical Centre Koshigaya Japan
2 shared publications - Yue Chen
Department of Dermatology Dokkyo Medical University Saitama Medical Centre Koshigaya Japan
2 shared publications - Sakiko Shimura
Department of Dermatology Dokkyo Medical University Saitama Medical Center Koshigaya Japan
1 shared publication
Latest Publications
- 21 October 2022
- Published by Wiley in Experimental Dermatology
- Vol. 32 (2) , 203-209
Oestrogen inhibits psoriasis‐like dermatitis induced by imiquimod in mice in relation to increased IL‐10 producing cells despite elevated expression of IL‐22, IL‐23, IL‐17 mRNA
Sex hormones influence the development and natural course of psoriasis. Here, we examined the effects of female sex hormones, particularly oestrogen, on psoriasis‐like dermatitis induced using topical imiquimod in mice that underwent either sham operation (Sham) or ovariectomy (OVX), with (hormone replacement treatment: HRT) or without 17β‐oestradiol targeting the maximum physiological levels. The number of neutrophils in the skin was higher in the order of OVX‐, Sham‐, and HRT‐treated mice. However, no significant difference was detected in the clinical scores among the three groups due to severe erythema and scale in a few mice out of HRT‐treated mice in a set of experiments. OVX‐ and HRT‐treated mice showed increased mRNA levels of interleukin (IL)‐22 and IL‐23 compared with Sham‐treated mice; increased IL‐10 mRNA levels were found in HRT‐treated mice, possibly due to an increased proportion of forkhead box P3 (Foxp3)‐ and IL‐10 positive large cells (possibly macrophages). In addition, HRT‐treated mice had a more compact stratum corneum with higher expression of loricrin and involucrin than OVX‐ and Sham‐treated mice. This study suggests that oestrogen has a dual potential in the pathogenesis of psoriasis: suppression of inflammation by enhancing IL‐10 production and enhancement of inflammation by induction of IL‐22 and IL‐23 expression.
- 21 October 2022
- Published by Wiley in Experimental Dermatology
- Vol. 32 (2) , 203-209
Oestrogen inhibits psoriasis‐like dermatitis induced by imiquimod in mice in relation to increased IL‐10 producing cells despite elevated expression of IL‐22, IL‐23, IL‐17 mRNA
Sex hormones influence the development and natural course of psoriasis. Here, we examined the effects of female sex hormones, particularly oestrogen, on psoriasis‐like dermatitis induced using topical imiquimod in mice that underwent either sham operation (Sham) or ovariectomy (OVX), with (hormone replacement treatment: HRT) or without 17β‐oestradiol targeting the maximum physiological levels. The number of neutrophils in the skin was higher in the order of OVX‐, Sham‐, and HRT‐treated mice. However, no significant difference was detected in the clinical scores among the three groups due to severe erythema and scale in a few mice out of HRT‐treated mice in a set of experiments. OVX‐ and HRT‐treated mice showed increased mRNA levels of interleukin (IL)‐22 and IL‐23 compared with Sham‐treated mice; increased IL‐10 mRNA levels were found in HRT‐treated mice, possibly due to an increased proportion of forkhead box P3 (Foxp3)‐ and IL‐10 positive large cells (possibly macrophages). In addition, HRT‐treated mice had a more compact stratum corneum with higher expression of loricrin and involucrin than OVX‐ and Sham‐treated mice. This study suggests that oestrogen has a dual potential in the pathogenesis of psoriasis: suppression of inflammation by enhancing IL‐10 production and enhancement of inflammation by induction of IL‐22 and IL‐23 expression.
- 28 June 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (12) , 1745-1753
Possible involvement of type 2 cytokines in alloknesis in mouse models of menopause and dry skin
Alloknesis, an abnormal itch sensation induced by innocuous stimuli, is a key phenomenon in the vicious itch‐scratch cycle in patients with atopic dermatitis. Dry skin and pruritus, including alloknesis, are major health problems in peri‐ and post‐menopausal women. We recently reported permeability barrier dysfunction in ovariectomized (OVX) mice—a model of menopause—and found that the dysfunction was related to dry skin. However, the mechanism of the itch remains unknown. Therefore, we examined touch‐ and pruritogen‐evoked alloknesis and epidermal innervation in OVX mice and acetone, diethyl ether and water (AEW)‐treated mice, for the experimental dry skin model. Both alloknesis and epidermal innervation were comparable in OVX and AEW mice. Neutralizing antibodies against IL‐4 and IL‐13 inhibited alloknesis in both OVX and AEW mice as early as 30 min after intradermal administration. Comparable values close to the measurement limit of IL‐4 were found in the skin of HRT and Sham mice as well as AEW and the control mice, but the levels of IL‐4 were within the measurement limit in OVX mice. We could not detect mRNAs of IL‐4 or IL‐13 in any groups of mice. On the other hand, the number of eosinophils and basophils was increased in OVX and AEW mice. These results suggest that impaired barrier function in cooperation with type 2 cytokines derived from eosinophils and basophils in the skin or with endogenous type 2 cytokine may trigger the development of alloknesis, and thus, these cytokines could be a therapeutic target for sensitive skin.
- 28 June 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (12) , 1745-1753
Possible involvement of type 2 cytokines in alloknesis in mouse models of menopause and dry skin
Alloknesis, an abnormal itch sensation induced by innocuous stimuli, is a key phenomenon in the vicious itch‐scratch cycle in patients with atopic dermatitis. Dry skin and pruritus, including alloknesis, are major health problems in peri‐ and post‐menopausal women. We recently reported permeability barrier dysfunction in ovariectomized (OVX) mice—a model of menopause—and found that the dysfunction was related to dry skin. However, the mechanism of the itch remains unknown. Therefore, we examined touch‐ and pruritogen‐evoked alloknesis and epidermal innervation in OVX mice and acetone, diethyl ether and water (AEW)‐treated mice, for the experimental dry skin model. Both alloknesis and epidermal innervation were comparable in OVX and AEW mice. Neutralizing antibodies against IL‐4 and IL‐13 inhibited alloknesis in both OVX and AEW mice as early as 30 min after intradermal administration. Comparable values close to the measurement limit of IL‐4 were found in the skin of HRT and Sham mice as well as AEW and the control mice, but the levels of IL‐4 were within the measurement limit in OVX mice. We could not detect mRNAs of IL‐4 or IL‐13 in any groups of mice. On the other hand, the number of eosinophils and basophils was increased in OVX and AEW mice. These results suggest that impaired barrier function in cooperation with type 2 cytokines derived from eosinophils and basophils in the skin or with endogenous type 2 cytokine may trigger the development of alloknesis, and thus, these cytokines could be a therapeutic target for sensitive skin.